SAHA (Vorinostat)
1 image
-
- Applikation
- Blocking Antibody (Inhibition)
- Produktmerkmale
-
HDAC inhibitor
Cutaneous T-cell lymphoma treatment
In vitro and in vivo effects on latent HIV infected T-Cells
-
-
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Lagerung
- RT/4 °C
-
- Hintergrund
- SAHA (suberoylanilide hydroxamic acid, Vorinostat, Zolinza™) is a histone deacetylase (HDAC) inhibitor that binds directly to the catalytic site of the enzyme thereby blocking substrate access. Sirt activator based on a dihydropyridine structural scaffold. EC150 (effective concentration able to increase enzyme activity by 150%) is 1 uM for Sirt1, 25 uM for Sirt2, and 50 uM for Sirt3. The compound is active in whole cells and arrests cell cycle at G1/S phase in U937 cells. SAHA inhibits class I and class II HDACs at around 50 nM and arrests cell growth in a wide variety of transformed cells in culture at 2.5-5.0 uM.
- Molekulargewicht
- 264.3 kDa
- CAS-Nummer
- 149647-78-9
-
Sie sind hier:
